Author

K. Uriu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 22 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 22 Approach:experimental assay· 18 Organism:human· 18 Organism:virus· 5 Assay:proteomics· 4 Approach:statistical model· 4 Approach:comparative / phylogenetic analysis· 2 Organism:C. elegans· 1

Frequent Co-Authors

The Genotype to Phenotype Japan (G2P-Japan) Consortium· 21 shared K. Sato· 19 shared J. Ito· 17 shared Y. Kosugi· 17 shared H. Asakura· 11 shared H. Nasser· 11 shared J. Zahradnik· 11 shared K. Sadamasu· 11 shared

Activity by Year

2020-2023 · peak 10/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

21 shared papersMicrobiology

The Genotype to Phenotype Japan (G2P-Japan) Consortium

Mutual co-authors in cluster

Author profile →

23 papers

Recent·Most cited

Virological characteristics of the SARS-CoV-2 JN.1 variant

Y. Kaku, K. Okumura, M. Padilla-Blanco, Y. Kosugi, K. Uriu, A. A. Hinay, L. Chen, A. Plianchaisuk, K. Kobiyama, K. J. Ishii, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Zahradnik, J. Ito, K. Sato

This study investigates the virological properties of the SARS-CoV-2 JN.1 variant, focusing on its mutations and potential immune evasion capabilities.

bioRxiv · Dec 8, 2023Microbiology

Antiviral humoral immunity against SARS-CoV-2 Omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals

Y. Kosugi, Y. Kaku, A. A. Hinay, Z. Guo, K. Uriu, M. Kihara, F. Saito, Y. Uwamino, J. Kuramochi, K. Shirakawa, A. Takaori-Kondo, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

The paper assesses the humoral immune response to XBB.1.5 vaccine in infection-naive and XBB-infected individuals against various SARS-CoV-2 variants.

bioRxiv · Nov 29, 2023Microbiology

Virological characteristics of the SARS-CoV-2 Omicron HK.3 variant harboring the "FLip" substitution

Y. Kosugi, A. Plianchaisuk, O. Putri, K. Uriu, Y. Kaku, A. A. Hinay, L. Chen, J. Kuramochi, K. Sadamasu, K. Yoshimura, H. Asakura, M. Nagashima, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Ito, K. Sato

This study investigates the virological properties of the SARS-CoV-2 HK.3 variant, a FLip variant with substitutions S:L455F and S:F456L, to assess its growth advantage.

bioRxiv · Nov 14, 2023 · PreprintMicrobiology

Virological characteristics of the SARS-CoV-2 BA.2.86 variant

T. Tamura, K. Mizuma, H. Nasser, S. Deguchi, M. Padilla-Blanco, K. Uriu, J. E. M. Tolentino, S. Tsujino, R. Suzuki, I. Kojima, N. Nao, R. Shimizu, M. Jonathan, Y. Kosugi, Z. Guo, , K. Sato

This study investigates the virological characteristics of the SARS-CoV-2 BA.2.86 variant, finding it has higher reproduction number than EG.5.1 but lower pathogenicity and replication capacity compared to BA.2.

bioRxiv · Nov 2, 2023Microbiology

Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant

S. Tsujino, S. Deguchi, T. Nomai, M. Padilla-Blanco, A. Plianchaisuk, L. Wang, M. M. Begum, K. Uriu, K. Mizuma, N. Nao, I. Kojima, T. Tsubo, J. Li, Y. Matsumura, M. Nagao, , Za

The paper investigates the virological features of the SARS-CoV-2 EG.5.1 variant, finding its fitness and antiviral sensitivity comparable to XBB.1.5, with structural differences in spike proteins.

bioRxiv · Oct 19, 2023Microbiology

Transmissibility, infectivity, and immune resistance of the SARS-CoV-2 BA.2.86 variant

K. Uriu, J. Ito, Y. Kosugi, Y. L. Tanaka, Y. Mugita, Z. Guo, A. A. Hinay, O. Putri, Y. Kim, R. Shimizu, M. M. Begum, M. Jonathan, The Genotype to Phenotype Japan (G2P-Japan) Consortium, A. Saito, T. Ikeda, K. Sato

This study investigates the transmissibility, infectivity, and immune resistance of the SARS-CoV-2 BA.2.86 variant, finding it to be highly immune evasive but with lower infectivity compared to other variants.

bioRxiv · Sep 7, 2023 · PreprintMicrobiology

Virological characteristics of the SARS-CoV-2 XBB.1.5 variant

T. Tamura, T. Irie, S. Deguchi, H. Yajima, M. Tsuda, H. Nasser, K. Mizuma, A. Plianchaisuk, S. Suzuki, K. Uriu, M. M. Begum, R. Shimizu, M. Jonathan, R. Suzuki, T. Kondo, , T. Fukuhara

The paper analyzes the virological characteristics of the SARS-CoV-2 XBB.1.5 variant, showing reduced pathogenicity and impaired MHC expression due to mutations in ORF8 and S.

bioRxiv · Aug 16, 2023 · PreprintMicrobiology

Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against Omicron subvariants including EG.5

Y. Kaku, Y. Kosugi, K. Uriu, J. Ito, J. Kuramochi, K. Sadamasu, K. Yoshimura, H. Asakura, M. Nagashima, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

This study evaluates the antiviral efficacy of XBB breakthrough infection sera against EG.5.1 and other Omicron subvariants, finding comparable neutralization titers and suggesting immune evasion is not the main driver of EG.5.1's spread.

bioRxiv · Aug 8, 2023 · PreprintMicrobiology

Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 variant

D. Yamasoba, K. Uriu, A. Plianchaisuk, Y. Kosugi, L. Pan, J. Zahradnik, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Ito, K. Sato

This study characterizes the virological features of the SARS-CoV-2 Omicron XBB.1.16 variant, showing increased transmissibility and immune evasion compared to previous variants.

The Lancet Infectious Diseases · Jun 1, 2023Peer-reviewedMicrobiology

Enhanced transmissibility, infectivity and immune resistance of the SARS-CoV-2 Omicron XBB.1.5 variant

K. Uriu, J. Ito, J. Zahradnik, S. Fujita, Y. Kosugi, G. Schreiber, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

This study evaluates the transmissibility, infectivity, and immune resistance of the SARS-CoV-2 Omicron XBB.1.5 variant, finding it more transmissible and resistant than previous variants.

bioRxiv · Jan 16, 2023Microbiology

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

T. Tamura, J. Ito, K. Uriu, J. Zahradnik, I. Kida, H. Nasser, M. Shofa, Y. Oda, S. Lytras, N. Nao, Y. Itakura, S. Deguchi, R. Suzuki, L. Wang, M. M. Begum, , K. Sato

This study identifies XBB as a SARS-CoV-2 variant resulting from recombination of BA.2 subvariants, showing increased resistance to neutralizing antibodies and enhanced fusogenicity compared to BA.2.75.

bioRxiv · Dec 27, 2022 · PreprintMicrobiology

Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

J. Ito, R. Suzuki, K. Uriu, Y. Itakura, J. Zahradnik, S. Deguchi, L. Wang, S. Lytras, T. Tamura, I. Kida, H. Nasser, M. Shofa, M. M. Begum, M. Tsuda, Y. Oda, , K. Sato

The paper investigates convergent evolution in SARS-CoV-2 Omicron subvariants, identifying five critical spike protein substitutions in BQ.1.1 that enhance viral fitness and antibody resistance.

bioRxiv · Dec 5, 2022Microbiology

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75

A. Saito, T. Tamura, J. Zahradnik, S. Deguchi, K. Tabata, I. Kimura, J. Ito, H. Nasser, M. Toyoda, K. Nagata, K. Uriu, Y. Kosugi, S. Fujita, D. Yamasoba, M. Shofa, , Kei Sato

This study investigates the virological characteristics of SARS-CoV-2 Omicron BA.2.75, finding it has higher transmissibility and pathogenicity compared to BA.2 and BA.5, but similar sensitivity to antiviral drugs.

bioRxiv · Jul 14, 2022Microbiology

Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5

I. Kimura, D. Yamasoba, T. Tamura, N. Nao, Y. Oda, S. Mitoma, J. Ito, H. Nasser, J. Zahradnik, K. Uriu, S. Fujita, Y. Kosugi, L. Wang, M. Tsuda, M. Kishimoto, , K. Sato

This study analyzes the virological characteristics of SARS-CoV-2 Omicron variants BA.2.12.1, BA.4, and BA.5, finding they have higher reproduction numbers, reduced neutralization by prior immunity, increased replication in lung cells, and greater pathogenicity in hamsters compared to BA.2.

bioRxiv · May 26, 2022Microbiology

Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies

D. Yamasoba, Y. Kosugi, I. Kimura, S. Fujita, K. Uriu, J. Ito, K. Sato, The Genotype to Phenotype Japan (G2P-Japan) Consortium

This study evaluates the sensitivity of new Omicron subvariants to eight therapeutic monoclonal antibodies, finding increased resistance in BA.4/5 to cilgavimab compared to BA.2.

bioRxiv · May 3, 2022Microbiology

SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant

I. Kimura, D. Yamasoba, H. Nasser, J. Zahradnik, Y. Kosugi, J. Wu, K. Nagata, K. Uriu, Y. L. Tanaka, J. Ito, R. Shimizu, T. S. Tan, E. P. Butlertanaka, H. Asakura, K. Sadamasu, , K. Sato

This study identifies the S375F mutation in the Omicron spike protein as responsible for its reduced cleavage efficiency, fusogenicity, and rapid spread.

bioRxiv · Apr 3, 2022Microbiology

Virological characteristics of SARS-CoV-2 BA.2 variant

D. Yamasoba, I. Kimura, H. Nasser, Y. Morioka, N. Nao, J. Ito, K. Uriu, M. Tsuda, J. Zahradnik, K. Shirakawa, R. Suzuki, M. Kishimoto, Y. Kosugi, K. Kobiyama, T. Hara, , Sawa

This study compares the virological characteristics of SARS-CoV-2 BA.2 and BA.1 variants, finding BA.2 has higher transmissibility, different antigenicity, greater replicative capacity, and higher pathogenicity in hamsters.

bioRxiv · Feb 14, 2022Microbiology

Cell size homeostasis under the circadian regulation of cell division in cyanobacteria

Y. Kitaguchi, H. Tei, K. Uriu

This study shows that circadian gating in cyanobacteria affects cell length and doubling time but maintains cell size homeostasis through a compensatory mechanism.

bioRxiv · Jan 25, 2022Cell Biology

Characterization of the immune resistance of SARS-CoV-2 Mu variant and the immunity induced by Mu infection

K. Uriu, P. Cardenas, E. Munoz, V. Barragan, Y. Kosugi, K. Shirakawa, A. Takaori-Kondo, Ecuador-COVID19 Consortium, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

This study identifies mutations in the SARS-CoV-2 Mu variant responsible for its immune resistance and shows that Mu-infected convalescent sera are broadly antiviral.

bioRxiv · Nov 23, 2021Microbiology

Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera

K. Uriu, I. Kimura, K. Shirakawa, A. Takaori-Kondo, T.-a. Nakada, A. Kaneda, The Genotype to Phenotype Japan (G2P-Japan) Consortium, S. Nakagawa, K. Sato

This study shows that Mu variant is highly resistant to neutralization by convalescent and vaccine sera compared to other variants.

bioRxiv · Sep 6, 2021Microbiology

SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity

A. Saito, T. Irie, R. Suzuki, T. Maemura, H. Nasser, K. Uriu, Y. Kosugi, K. Shirakawa, K. Sadamasu, I. Kimura, J. Ito, J. Wu, K. Iwatsuki-Horimoto, M. Ito, S. Yamayoshi, , K. Sato

This study shows the P681R mutation in the SARS-CoV-2 spike protein enhances fusogenicity and pathogenicity in the Delta variant compared to the prototypic virus.

bioRxiv · Jun 17, 2021Microbiology

An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity

C. Motozono, M. Toyoda, J. Zahradnik, T. Ikeda, A. Saito, T. S. Tan, I. Ngare, H. Nasser, I. Kimura, K. Uriu, Y. Kosugi, S. Torii, A. Yonekawa, N. Shimono, Y. Nagasaki, , K. Sato

This study identifies two SARS-CoV-2 mutations, L452R and Y453F, that evade HLA-restricted cellular immunity and increase viral infectivity.

bioRxiv · Apr 2, 2021Microbiology

SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant

Y. Konno, I. Kimura, K. Uriu, M. Fukushi, T. Irie, Y. Koyanagi, S. Nakagawa, K. Sato

This paper shows that SARS-CoV-2 ORF3b is a potent interferon antagonist, with a naturally occurring longer variant enhancing its anti-interferon activity in severe COVID-19 cases.

bioRxiv · May 11, 2020Microbiology